NPPB and heart disorder: In patients with NT-proBNP > 125 pg/mL without cardiac disease randomized into a “control” group and an “intensified” group (receiving up-titration of RAS antagonists and betablockers), a significant reduction in the primary endpoint (composite CV death and CV hospitalization) (HR: 0.351, p = 0.044) was observed in the intensified group [30,31].